Myrobalan Therapeutics Presents Collaborative Research Featuring GPR17 Antagonist at ACTRIMS 2026

Myrobalan Therapeutics announced the presentation of a scientific poster at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum highlighting collaborative preclinical research conducted with the laboratory of Ethan G. Hughes, PhD, Associate Professor of Cell and Developmental Biology at the University of Colorado Anschutz School of Medicine.

The poster, titled “Premyelinating Oligodendrocyte Survival Drives Regenerative Oligodendrogenesis Following Demyelinating Injury,” describes studies investigating mechanisms that support remyelination following demyelinating injury in mice. The research includes evaluation of a Myrobalan‑developed GPR17 antagonist and its effects on oligodendrocyte regeneration dynamics and survival of premyelinating oligodendrocytes.

Findings presented at ACTRIMS suggest that, following demyelinating injury, enhanced survival of premyelinating oligodendrocytes contributes to regenerative oligodendrogenesis, and that modulation of this process with a GPR17 antagonist can influence remyelination outcomes in vivo.

This work reflects an ongoing scientific collaboration between Myrobalan Therapeutics and the Hughes laboratory, integrating Myrobalan’s therapeutic development efforts with advanced in vivo imaging and myelin biology expertise. The data support Myrobalan’s broader research strategy focused on understanding and promoting central nervous system repair in demyelinating disease.

The ACTRIMS Forum is a leading international conference dedicated to advancing research and treatment for multiple sclerosis and related neuroimmunological disorders. Presentation of this collaborative work underscores Myrobalan’s commitment to rigorous science and engagement with the MS research community.